non-small cell lung cancer

Burning Rock also said it will continue to develop companion diagnostics-related products based on next-generation sequencing technology.

The algorithm provides automated assessments of objective and reproducible scanned slide images that can help with diagnosis and targeted treatment options.

The assay will identify patients with mutations in HER2 who may be eligible for treatment with a HER2-directed antibody-drug-conjugate developed by Daiichi.

The companies are developing a lung cancer liquid biopsy assay that will run on desktop sequencers, with plans to apply for regulatory clearance in China.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

ArcherDX said the firms aim to apply minimal residual disease monitoring in clinical-trial protocols and for future therapy optimization.

Under the agreement, NeoGenomics will also make a $25 million equity investment in Inivata with an option to buy the company outright.

ArcherDx will develop sequencing-based circulating tumor DNA assays for use in AstraZeneca's recently launched Phase III MERMAID-1 trial of durvalumab (Imfinzi).

The approval was based on data showing superior efficacy for Alunbrig compared to Pfizer's Xalkori, especially in patients with brain metastasis.